Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-LTR povorcitinib long-term rollover study
NL-OMON60394Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of povorcitinib in hidradenitis suppurativa (HS), Vitiligo and prurigo nodularis (PN) (3 cohorts), sponsored by Incyte. Primary endpoint: Treatment-emergent adverse events. Started Jan 2026; status: recruiting.
02
Drugs
povorcitinib
03
Conditions
hidradenitis suppurativa (HS)Vitiligoprurigo nodularis (PN)
Beyond the preview
Go deeper on NL-OMON60394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60394.